Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

It has been exciting for me to relive the successful mission of Apollo 11 to the moon on July 20, 1969. Were you alive on that summer day when histo...

View Blog Post
Blog Post

Patient education has become a key element of the patient care and treatment experience. Whether at office visits, in care settings, or through patient portals, distributing information on conditions, medications, and follow-up...

View Blog Post
Blog Post

Everyday there are more news headlines about policymakers addressing different approaches to lowering healthcare and prescription drug costs. This spring alone saw news about the

View Blog Post

Filter by Type

Sign up to receive the latest news and information!

Sign Up